By efrat|2023-12-06T07:49:31+00:00December 11th, 2023|All|Comments Off on Dec 12th 2023- Prof. Arnold Ganser – How I Treat Refractory and Relapsed Acute Myeloid Leukemia
By efrat|2023-12-03T08:05:44+00:00December 4th, 2023|All|Comments Off on Dec 5th 2023- Prof. Wolfgang Bethge- Outcomes of Axicabtagene Ciloleucel in PMBCL Compare Favorably with those in DLBCL: a GLA/DRST Registry Study
By efrat|2023-11-21T11:16:59+00:00November 27th, 2023|All|Comments Off on Nov 28th 2023- Prof. Ibrahim Yakoub-Agha- Nonrelapse Mortality After CAR T-cell Therapy for Large B-cell Lymphoma: a LYSA Study from the DESCAR-T Registry
By efrat|2023-11-19T06:54:42+00:00November 20th, 2023|All|Comments Off on Nov 21st 2023- Prof. Moshe Mittelman- A Randomized Comparison of CPX-351 and FLAG-Ida in Adverse Karyotype AML and High-Risk MDS: The UK NCRI AML19 Trial
By efrat|2023-11-08T06:35:37+00:00November 13th, 2023|All|Comments Off on Nov 14th 2023- Dr. Bipin Savani- Vitamin C and D Supplementation in Acute Myeloid Leukemia
By efrat|2023-11-05T06:48:14+00:00November 4th, 2023|All|Comments Off on Nov 6th 2023- Prof. Attilio Olivieri- Incidence, Clinical Presentation, Risk Factors, Outcomes, and Biomarkers in De Novo Late Acute GVHD
By efrat|2023-10-29T10:30:21+00:00October 26th, 2023|All|Comments Off on Oct 30th 2023- Prof. Robert Zeiser- Phase 2 Study of Natalizumab Plus Standard Corticosteroid Treatment for High-Risk Acute GVHD
By efrat|2023-10-22T07:35:02+00:00October 20th, 2023|All|Comments Off on Oct 23rd 2023- Prof. Didier Blaise- Real World Experience of CAR T Cell Therapy in Older Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma
By efrat|2023-10-12T06:33:16+00:00October 15th, 2023|All|Comments Off on Oct 16th 2023- Dr. Enrique Ocio- Melflufen Plus Dexamethasone and Daratumumab or Bortezomib in Relapsed/Refractory MM
